Hypertension - Pipeline Review, H2 2016

Date: December 21, 2016
Pages: 551
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HF1F4E95D70EN
Leaflet:

Download PDF Leaflet

Hypertension - Pipeline Review, H2 2016
Hypertension - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension – Pipeline Review, H2 2016, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 32, 28, 26, 85 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 8 molecules, respectively.

Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Hypertension Overview
Therapeutics Development
Hypertension - Therapeutics under Development by Companies
Hypertension - Therapeutics under Investigation by Universities/Institutes
Hypertension - Pipeline Products Glance
Hypertension - Products under Development by Companies
Hypertension - Products under Investigation by Universities/Institutes
Hypertension - Companies Involved in Therapeutics Development
Hypertension - Therapeutics Assessment
Drug Profiles
Hypertension - Dormant Projects
Hypertension - Discontinued Products
Hypertension - Product Development Milestones
Appendix 527

LIST OF TABLES

Number of Products under Development for Hypertension, H2 2016
Number of Products under Development for Hypertension - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Hypertension - Pipeline by A1M Pharma AB, H2 2016
Hypertension - Pipeline by AbbVie Inc, H2 2016
Hypertension - Pipeline by Actelion Ltd, H2 2016
Hypertension - Pipeline by Afferent Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Anacor Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by AnGes MG Inc, H2 2016
Hypertension - Pipeline by APT Therapeutics Inc, H2 2016
Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016
Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H2 2016
Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Bayer AG, H2 2016
Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2016
Hypertension - Pipeline by Biolab Farmaceutica Ltda, H2 2016
Hypertension - Pipeline by BioRestorative Therapies Inc, H2 2016
Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016
Hypertension - Pipeline by Cellceutix Corp, H2 2016
Hypertension - Pipeline by Celsion Corp, H2 2016
Hypertension - Pipeline by Celtaxsys Inc, H2 2016
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
Hypertension - Pipeline by CJ HealthCare Corp, H2 2016
Hypertension - Pipeline by Complexa Inc, H2 2016
Hypertension - Pipeline by Conatus Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Corion Biotech Srl, H2 2016
Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Cytokinetics Inc, H2 2016
Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016
Hypertension - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Hypertension - Pipeline by DiaMedica Inc, H2 2016
Hypertension - Pipeline by Eli Lilly and Company, H2 2016
Hypertension - Pipeline by Esperion Therapeutics Inc, H2 2016
Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Hypertension - Pipeline by Ferring International Center SA, H2 2016
Hypertension - Pipeline by Galectin Therapeutics Inc, H2 2016
Hypertension - Pipeline by Genextra Spa, H2 2016
Hypertension - Pipeline by Gilead Sciences Inc, H2 2016
Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2016
Hypertension - Pipeline by Glenveigh Medical LLC, H2 2016
Hypertension - Pipeline by HanAll Biopharma Co Ltd, H2 2016
Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
Hypertension - Pipeline by HitGen LTD, H2 2016
Hypertension - Pipeline by Innopharmax Inc, H2 2016
Hypertension - Pipeline by Insmed Inc, H2 2016
Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016
Hypertension - Pipeline by Johnson & Johnson, H2 2016
Hypertension - Pipeline by JW Pharmaceutical Corp, H2 2016
Hypertension - Pipeline by Kowa Company Ltd, H2 2016
Hypertension - Pipeline by Leading BioSciences Inc, H2 2016
Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2016
Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2016
Hypertension - Pipeline by LFB SA, H2 2016
Hypertension - Pipeline by LG Life Science LTD, H2 2016
Hypertension - Pipeline by LinXis BV, H2 2016
Hypertension - Pipeline by Liquidia Technologies Inc, H2 2016
Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016
Hypertension - Pipeline by MannKind Corp, H2 2016
Hypertension - Pipeline by Mast Therapeutics Inc, H2 2016
Hypertension - Pipeline by Merck & Co Inc, H2 2016
Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2016
Hypertension - Pipeline by miRagen Therapeutics Inc, H2 2016
Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016
Hypertension - Pipeline by Morphogen-IX Ltd, H2 2016
Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
Hypertension - Pipeline by Nippon Kayaku Co Ltd, H2 2016
Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2016
Hypertension - Pipeline by Novartis AG, H2 2016
Hypertension - Pipeline by Noxamet Ltd, H2 2016
Hypertension - Pipeline by Omeros Corp, H2 2016
Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2016
Hypertension - Pipeline by Pfizer Inc, H2 2016
Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Pluristem Therapeutics Inc, H2 2016
Hypertension - Pipeline by Polyphor Ltd, H2 2016
Hypertension - Pipeline by Proteo Inc, H2 2016
Hypertension - Pipeline by Pulmokine Inc, H2 2016
Hypertension - Pipeline by Quantum Genomics SA, H2 2016
Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by RedHill Biopharma Ltd, H2 2016
Hypertension - Pipeline by Respira Therapeutics Inc, H2 2016
Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2016
Hypertension - Pipeline by Sanofi, H2 2016
Hypertension - Pipeline by Selten Pharma Inc, H2 2016
Hypertension - Pipeline by Serodus ASA, H2 2016
Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016
Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016
Hypertension - Pipeline by Simcere Pharmaceutical Group, H2 2016
Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2016
Hypertension - Pipeline by Suda Ltd, H2 2016
Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
Hypertension - Pipeline by The Medicines Company, H2 2016
Hypertension - Pipeline by Theravance Biopharma Inc, H2 2016
Hypertension - Pipeline by Toray Industries Inc, H2 2016
Hypertension - Pipeline by Torrent Pharmaceuticals Ltd, H2 2016
Hypertension - Pipeline by TSH Biopharm Corporation Ltd, H2 2016
Hypertension - Pipeline by United Therapeutics Corp, H2 2016
Hypertension - Pipeline by VBS Pharmaceuticals, H2 2016
Hypertension - Pipeline by Vectura Group Plc, H2 2016
Hypertension - Pipeline by VG Life Sciences Inc, H2 2016
Hypertension - Pipeline by Vicore Pharma AB, H2 2016
Hypertension - Pipeline by XORTX Pharma Corp, H2 2016
Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H2 2016
Hypertension - Pipeline by Yuhan Corp, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hypertension - Dormant Projects, H2 2016
Hypertension - Dormant Projects (Contd..1), H2 2016
Hypertension - Dormant Projects (Contd..2), H2 2016
Hypertension - Dormant Projects (Contd..3), H2 2016
Hypertension - Dormant Projects (Contd..4), H2 2016
Hypertension - Dormant Projects (Contd..5), H2 2016
Hypertension - Dormant Projects (Contd..6), H2 2016
Hypertension - Dormant Projects (Contd..7), H2 2016
Hypertension - Dormant Projects (Contd..8), H2 2016
Hypertension - Dormant Projects (Contd..9), H2 2016
Hypertension - Dormant Projects (Contd..10), H2 2016
Hypertension - Dormant Projects (Contd..11), H2 2016
Hypertension - Dormant Projects (Contd..12), H2 2016
Hypertension - Dormant Projects (Contd..13), H2 2016
Hypertension - Dormant Projects (Contd..14), H2 2016
Hypertension - Dormant Projects (Contd..15), H2 2016
Hypertension - Dormant Projects (Contd..16), H2 2016
Hypertension - Dormant Projects (Contd..17), H2 2016
Hypertension - Dormant Projects (Contd..18), H2 2016
Hypertension - Dormant Projects (Contd..19), H2 2016
Hypertension - Dormant Projects (Contd..20), H2 2016
Hypertension - Dormant Projects (Contd..21), H2 2016
Hypertension - Dormant Projects (Contd..22), H2 2016
Hypertension - Dormant Projects (Contd..23), H2 2016
Hypertension - Dormant Projects (Contd..24), H2 2016
Hypertension - Dormant Projects (Contd..25), H2 2016
Hypertension - Discontinued Products, H2 2016
Hypertension - Discontinued Products (Contd..1), H2 2016
Hypertension - Discontinued Products (Contd..2), H2 2016 537

LIST OF FIGURES

Number of Products under Development for Hypertension, H2 2016
Number of Products under Development for Hypertension - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ocular Hypertension - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 118 pages
Portal Hypertension - Pipeline Review, H1 2016 US$ 2,000.00 Mar, 2016 · 73 pages
Omeros Corporation - Product Pipeline Review - 2016 US$ 1,500.00 Aug, 2016 · 115 pages
Longevity Biotech, Inc - Product Pipeline Review - 2015 US$ 1,500.00 Feb, 2015 · 29 pages

Ask Your Question

Hypertension - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: